RGD Reference Report - Tumor necrosis factor-alpha plays an important role in restenosis development. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Tumor necrosis factor-alpha plays an important role in restenosis development.

Authors: Monraats, PS  Pires, NM  Schepers, A  Agema, WR  Boesten, LS  De Vries, MR  Zwinderman, AH  De Maat, MP  Doevendans, PA  De Winter, RJ  Tio, RA  Waltenberger, J  't Hart, LM  Frants, RR  Quax, PH  Van Vlijmen, BJ  Havekes, LM  Van der Laarse, A  Van der Wall, EE  Jukema, JW 
Citation: Monraats PS, etal., FASEB J. 2005 Dec;19(14):1998-2004.
RGD ID: 1580322
Pubmed: PMID:16319143   (View Abstract at PubMed)
DOI: DOI:10.1096/fj.05-4634com   (Journal Full-text)

Genetic factors appear to be important in the restenotic process after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. TNFalpha, a key regulator of inflammatory responses, may exert critical influence on the development of restenosis after PCI. The GENetic DEterminants of Restenosis (GENDER) project included 3104 patients who underwent a successful PCI. Systematic genotyping for six polymorphisms in the TNFalpha gene was performed. The role of TNFalpha in restenosis was also assessed in ApoE*3-Leiden mice, TNFalpha knockout mice, and by local delivery of a TNFalpha biosynthesis inhibitor, thalidomide. The -238G-1031T haplotype of the TNFalpha gene increased clinical and angiographic risk of restenosis (P=0.02 and P=0.002, respectively). In a mouse model of reactive stenosis, arterial TNFalpha mRNA was significantly time-dependently up-regulated. Mice lacking TNFalpha or treated locally with thalidomide showed a reduction in reactive stenosis (P=0.01 and P=0.005, respectively). Clinical and preclinical data indicate that TNFalpha plays an important role in restenosis. Therefore, TNFalpha genotype may be used as a risk marker for restenosis and may contribute to individual patient screening prior to PCI in clinical practice. Inhibition of TNFalpha may be an anti-restenotic target strategy.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
TNFHumancoronary restenosis  IAGP  RGD 
TnfRatcoronary restenosis  ISOTNF (Homo sapiens) RGD 
TnfMousecoronary restenosis  ISOTNF (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Tnf  (tumor necrosis factor)

Genes (Mus musculus)
Tnf  (tumor necrosis factor)

Genes (Homo sapiens)
TNF  (tumor necrosis factor)


Additional Information